shot-button
Subscription Subscription
Home > News > World News > Article > India US to begin trials for Ayurvedic formulations against COVID 19

India, US to begin trials for Ayurvedic formulations against COVID-19

Updated on: 09 July,2020 10:08 AM IST  |  Washington D.C.
PTI |

The Indo-US Science Technology Forum (IUSSTF) has always been instrumental in promoting excellence in science, technology, and innovation through collaborative activities

India, US to begin trials for Ayurvedic formulations against COVID-19

This picture has been used for representation purpose

Ayurvedic practitioners and researchers in India and the US are planning to initiate joint clinical trials for Ayurveda formulations against the novel coronavirus, the Indian envoy here has said. In a virtual interaction with a group of eminent Indian-American scientists, academicians, and doctors on Wednesday, Indian Ambassador to the US Taranjit Singh Sandhu said the vast network of institutional engagements have brought scientific communities between the two countries together in the fight against COVID-19.


"Our Institutions have also been collaborating to promote Ayurveda through joint research, teaching and training programs. Ayurvedic practitioners and researchers in both the countries are planning to initiate joint clinical trials of Ayurvedic formulations against COVID-19," Sandhu said. "Our scientists have been exchanging knowledge and research resources on this front," he said.


The Indo-US Science Technology Forum (IUSSTF) has always been instrumental in promoting excellence in science, technology, and innovation through collaborative activities. To address COVID-19-related challenges, the IUSSTF had given a call to support joint research and start-up engagements. Large number of proposals are being reviewed on fast track mode by the experts on both the sides, he said.


"Indian pharmaceutical companies are global leaders in producing affordable low-cost medicines and vaccines and will play an important role in the fight against this pandemic," Sandhu said. According to the ambassador, there are at least three ongoing collaborations between Indian vaccine companies with US-based institutions.
These collaborations would be beneficial not just to India and the US, but also for the billions who would need to be vaccinated against COVID-19 across the world, he noted.

Asserting that innovation will be the key driver in pandemic response and recovery, he said tech-companies and start-ups have already begun to take the lead in this direction. "Telemedicine and telehealth will evolve as will other digital platforms across sectors," he said. Noting that there has been longstanding collaboration between India and US in health sector, he said scientists have been working together in several programs to understand important diseases at basic and clinical level.
Many such programs have been focused on translational research to develop new therapeutics and diagnostics.

There are over 200 ongoing NIH funded projects in India involving 20 institutions from NIH network and several eminent institutions in India engaged in a wide spectrum of research areas to create health care solutions, the senior diplomat said. The collaboration under Vaccine Action Program (VAP) resulted in development of ROTAVAC vaccine against rota virus which causes severe diarrhea in children.

The vaccine was developed by an Indian company (Bharat Biotech) at an affordable cost. It has been commercialised and introduced in the Expanded Program on Immunisation. Development of many other vaccines such as TB, Influenza, Chikungunya are also in progress under the VAP, he said. "As I speak, the VAP meeting is in progress where experts from both countries are deeply engaged in technical discussions to expedite development of COVID-19 vaccine," Sandhu said in his remarks.

During the interaction, the eminent experts appreciated India's handling of the COVID-19 pandemic and offered their valuable suggestions and best practices in this regard.

They shared their ideas on deepening the knowledge partnership between India and the US. The experts who took part in interaction, were drawn from a wide-ranging fields including artificial intelligence, quantum information science, biomedical engineering, robotics, mechanical engineering, earth and ocean science, virology, physics, astrophysics, and health sciences.

Prominent among those who attended the virtual interaction were Subhash Kak Regents Professor at Oklahoma State University, Dr Vijay Kuchroo, Samuel L Wasserstrom Professor of Neurology at Harvard Medical School, Dr Ashish M Kamat, Professor of Urology at MD Anderson Cancer Center, Ashutosh Chilkoti, Alan L Kaganov Professor of Biomedical Engineering and Chair of the Department of Biomedical Engineering at Duke University; and Prof Manu Prakash, professor in Department of Bioengineering at Sandford University, among others.

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK